FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivoDaniel Cejka, Volker Wacheck|British Journal of Cancer|2009Cited by 39
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsVolker Wacheck, Richard F. Schlenk|Cancer Management and Research|2011Cited by 5